Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX-4 With or Without Cetuximab in Stage III Colon Cancer
NCT00265811Phase 3Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Nov 2005
- Primary completion
- Nov 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab in colon cancer (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Disease-Free Survival at 3 years. Started Nov 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT00265811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00265811.